BioSpace News Archive

Summit Therapeutics Inc. announced that Dr. Maky Zangenah, DDS, has been named co-Chief Executive Officer, and Paul Sekhri has risen to the title of CEO at vTv Therapeutics.

The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.

The DESTINY-Breast04 trial introduces a new option for breast cancer diagnosis – HER2-low. The trial data received a standing ovation from thousands of oncologists at this year’s ASCO meeting.

Pfizer and BioNTech initiated a Phase II trial of an enhanced COVID-19 vaccine while fending off lawsuits against CureVac and Alnylam over their technology.

Only weeks after announcing a new chief executive officer and chief medical officer, Editas Medicine reported promising early data for its Phase I/II RUBY trial of EDIT-301 for severe sickle cell disease (SCD).

SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.

Teva expects to finalize and complete the documentation needed in the coming weeks, followed by a nationwide sign-on process for states, subdivisions and Native American tribes.

On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.

According to Transparency Market Research’s latest report on the global clinical trials management system market for the historical period 2017–2018 and forecast period 2019–2027, rising demand for new therapies and increasing research and developmental activities to drive the global clinical trials management system market during the forecast period

Wilmington, Delaware, United States, Transparency Market Research Inc.: Carrier screening is a genetic test used to determine if a healthy person is a carrier of a recessive genetic disease or a gene for certain genetic disorders.